Movement Alert｜WuXi Biologics Rises 3.45% in Regular Trading, MFG8 Drug Substance Facility FDA Approval Continues to Boost Sentiment

Market Focus07-10

On July 10, WuXi Biologics rose 3.45% in regular trading, trading at HKD 38.28/share, with turnover of HKD 147 million.

On the news front, the company's MFG8 drug substance manufacturing facility successfully passed the U.S. FDA Pre-License Inspection (PLI), marking a critical milestone toward commercial supply of a potential blockbuster autoimmune therapy. The certification validates the facility's compliance with international high-standard manufacturing quality systems, paving the way for large-scale, stable drug production. The approval of the related therapy is expected to accelerate accordingly.

Additionally, UBS previously raised its target price for WuXi Biologics to HKD 51.1, maintaining a Buy rating, implying significant upside from the current share price. The company has also maintained a high-frequency buyback pace, repurchasing approximately HKD 99.82 million worth of shares on July 7 alone, with cumulative buybacks reaching HKD 1.272 billion year-to-date.

Within the Life Sciences Tools and Services sector, WUXI APPTEC up 3.69%, PHARMARON up 4.55%, WUXI XDC up 2.02%, XTALPI up 0.26%, INSILICO down 1.46%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185358101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185358101","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WuXi Biologics Rises 3.45% in Regular Trading, MFG8 Drug Substance Facility FDA Approval Continues to Boost Sentiment","media":"Market Focus","content":"<p><p>On July 10, WuXi Biologics rose 3.45% in regular trading, trading at HKD 38.28/share, with turnover of HKD 147 million.</p><p>On the news front, the company's MFG8 drug substance manufacturing facility successfully passed the U.S. FDA Pre-License Inspection (PLI), marking a critical milestone toward commercial supply of a potential blockbuster autoimmune therapy. The certification validates the facility's compliance with international high-standard manufacturing quality systems, paving the way for large-scale, stable drug production. The approval of the related therapy is expected to accelerate accordingly.</p><p>Additionally, UBS previously raised its target price for WuXi Biologics to HKD 51.1, maintaining a Buy rating, implying significant upside from the current share price. The company has also maintained a high-frequency buyback pace, repurchasing approximately HKD 99.82 million worth of shares on July 7 alone, with cumulative buybacks reaching HKD 1.272 billion year-to-date.</p><p>Within the Life Sciences Tools and Services sector, WUXI APPTEC up 3.69%, PHARMARON up 4.55%, WUXI XDC up 2.02%, XTALPI up 0.26%, INSILICO down 1.46%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi Biologics Rises 3.45% in Regular Trading, MFG8 Drug Substance Facility FDA Approval Continues to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi Biologics Rises 3.45% in Regular Trading, MFG8 Drug Substance Facility FDA Approval Continues to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, WuXi Biologics rose 3.45% in regular trading, trading at HKD 38.28/share, with turnover of HKD 147 million.</p><p>On the news front, the company's MFG8 drug substance manufacturing facility successfully passed the U.S. FDA Pre-License Inspection (PLI), marking a critical milestone toward commercial supply of a potential blockbuster autoimmune therapy. The certification validates the facility's compliance with international high-standard manufacturing quality systems, paving the way for large-scale, stable drug production. The approval of the related therapy is expected to accelerate accordingly.</p><p>Additionally, UBS previously raised its target price for WuXi Biologics to HKD 51.1, maintaining a Buy rating, implying significant upside from the current share price. The company has also maintained a high-frequency buyback pace, repurchasing approximately HKD 99.82 million worth of shares on July 7 alone, with cumulative buybacks reaching HKD 1.272 billion year-to-date.</p><p>Within the Life Sciences Tools and Services sector, WUXI APPTEC up 3.69%, PHARMARON up 4.55%, WUXI XDC up 2.02%, XTALPI up 0.26%, INSILICO down 1.46%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1185358101","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185358101","pubTimestamp":1783648285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, WuXi Biologics rose 3.45% in regular trading, trading at HKD 38.28/share, with turnover of HKD 147 million.On the news front, the company's MFG8 drug substance manufacturing facility...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨3.45%，MFG8原料药工厂FDA批准继续提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On July 10, WuXi Biologics rose 3.45% in regular trading, trading at HKD 38.28/share, with turnover of HKD 147 million.On the news front, the company's MFG8 drug substance manufacturing facility successfully passed the U.S. FDA Pre-License Inspection (PLI), marking a critical milestone toward commercial supply of a potential blockbuster autoimmune therapy. The certification validates the facility's compliance with international high-standard manufacturing quality systems, paving the way for large-scale, stable drug production. The approval of the related therapy is expected to accelerate accordingly.Additionally, UBS previously raised its target price for WuXi Biologics to HKD 51.1, maintaining a Buy rating, implying significant upside from the current share price. The company has also maintained a high-frequency buyback pace, repurchasing approximately HKD 99.82 million worth of shares on July 7 alone, with cumulative buybacks reaching HKD 1.272 billion year-to-date.Within the Life Sciences Tools and Services sector, WUXI APPTEC up 3.69%, PHARMARON up 4.55%, WUXI XDC up 2.02%, XTALPI up 0.26%, INSILICO down 1.46%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185358101","isCrawlerRequest":true}